Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BioDirection completes $4mm Series B round

Executive Summary

BioDirection Inc. (brain injury diagnostics) completed a $4mm Series B convertible preferred stock sale to Provident Healthcare Capital (a fund affiliated with Provident Healthcare Partners) and other undisclosed investors. The financing will support ongoing development for the company's Tbit, a rapid point-of-care blood test to diagnose and gauge the severity of traumatic brain injury (TBI) that uses its Harvard-licensed biosensing nanowire technology to detect and measure, in less than 90-seconds, biomarker proteins released from the brain after an injury occurs.
Deal Industry
  • In Vitro Diagnostics
  • Medical Devices
    • Diagnostic Equipment & Supplies
    • Monitoring Equipment & Devices
  • In Vitro Diagnostics
    • Biosensors
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Nanotechnology, Chips, etc.
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies